The platform introduces a patent-pending AI system that monitors specimen collection in real time. By identifying errors as they occur, the technology aims to reduce failed collection costs by up to 90 percent. When issues arise that the AI cannot resolve, human assistance is available to guide the patient, minimizing the need for repeat shipments and accelerating diagnostic timelines.
In section Releases
Diagnostic.ly Launches AI-Driven Platform to Automate At-Home Care
Seventy percent of health journeys begin with at-home testing, yet patients frequently struggle with ambiguous instructions and failed sample collections. Fort Worth-based Diagnostic.ly is addressing these gaps with a new platform expansion designed to automate clinical workflows from the initial test order through to verifying treatment efficacy.
Beyond collection, the update enables healthcare organizations to implement 'Test & Treat' and 'Treat & Prove' workflows. These tools automatically generate product recommendations—such as supplements or hormonal therapies—based on test results, while scheduling follow-up testing to quantify patient outcomes. For independent laboratories, the company has added competitive benchmarking, profitability analysis, and automated proposal generation. CEO David Shor stated that these features are intended to help labs improve their service quality and market positioning rather than relying on price-cutting strategies.
Comments (0)
No comments yet. Be the first!